| Company | GeneFrontier Corporation | ||
| Established | February 14, 2003 | ||
| Capital | 10 million yen | ||
| Board of Directors |
|
||
| Shareholders |
Takashi Ebihara |
||
| Business |
1. Provider of Innovative Genomic Drug Discovery Research Services: ♦ Customized Human Combinatorial Monoclonal Antibody Contract Service, using Phage Display Technology partnered with Antibody by Design , a division of MorphoSys AG (Munich, Germany) 2. Monoclonal Antibody Therapeutic Drug Discovery: ♦ Discovery of innovative Antibody Drugs partnering with various academic institutes |
||
| Contact | Todai-Kashiwa Venture Plaza Rm#308 5-4-19, Kashiwa-no-Ha, Kashiwa, Chiba 277-0882, JAPAN Phone: +81-4-7137-6301 Facsimile: +81-4-7132-7530 E-mail: info@genefrontier.com |
